331 related articles for article (PubMed ID: 31724750)
1. Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting.
Bertoni S; Machness A; Tiboni M; Bártolo R; Santos HA
Biopolymers; 2020 Jan; 111(1):e23336. PubMed ID: 31724750
[TBL] [Abstract][Full Text] [Related]
2. Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives.
Chen M; Lan H; Jin K; Chen Y
Drug Deliv; 2023 Dec; 30(1):2219427. PubMed ID: 37288799
[TBL] [Abstract][Full Text] [Related]
3. [Reactive oxygen species stimuli-responsive nanocarriers].
Zhou W; Yang K; Zhao B; Zhang L; Zhang Y
Se Pu; 2021 Feb; 39(2):118-124. PubMed ID: 34227343
[TBL] [Abstract][Full Text] [Related]
4. Biocompatible reactive oxygen species (ROS)-responsive nanoparticles as superior drug delivery vehicles.
Zhang D; Wei Y; Chen K; Zhang X; Xu X; Shi Q; Han S; Chen X; Gong H; Li X; Zhang J
Adv Healthc Mater; 2015 Jan; 4(1):69-76. PubMed ID: 25147049
[TBL] [Abstract][Full Text] [Related]
5. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease.
Li S; Xie A; Li H; Zou X; Zhang Q
J Control Release; 2019 Dec; 316():66-78. PubMed ID: 31682913
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges.
Nunes R; Neves JD; Sarmento B
Nanomedicine (Lond); 2019 Oct; 14(19):2631-2644. PubMed ID: 31612773
[TBL] [Abstract][Full Text] [Related]
7. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.
Hua S; Marks E; Schneider JJ; Keely S
Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle targeting to inflamed tissues of the gastrointestinal tract.
Moulari B; Beduneau A; Pellequer Y; Lamprecht A
Curr Drug Deliv; 2013 Feb; 10(1):9-17. PubMed ID: 22998041
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy.
Zhao P; Xia X; Xu X; Leung KKC; Rai A; Deng Y; Yang B; Lai H; Peng X; Shi P; Zhang H; Chiu PWY; Bian L
Nat Commun; 2021 Dec; 12(1):7162. PubMed ID: 34887414
[TBL] [Abstract][Full Text] [Related]
10. Advanced drug-delivery systems: mechanoresponsive nanoplatforms applicable in atherosclerosis management.
Nurhidayah D; Maruf A; Zhang X; Liao X; Wu W; Wang G
Nanomedicine (Lond); 2019 Dec; 14(23):3105-3122. PubMed ID: 31823682
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species-responsive nanoplatforms for nucleic acid-based gene therapy of cancer and inflammatory diseases.
Zhu D; Chen W; Lin W; Li Y; Liu X
Biomed Mater; 2021 Jun; 16(4):. PubMed ID: 34116517
[TBL] [Abstract][Full Text] [Related]
12. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis.
Dou Y; Chen Y; Zhang X; Xu X; Chen Y; Guo J; Zhang D; Wang R; Li X; Zhang J
Biomaterials; 2017 Oct; 143():93-108. PubMed ID: 28778000
[TBL] [Abstract][Full Text] [Related]
13. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective.
Hunter AC; Elsom J; Wibroe PP; Moghimi SM
Nanomedicine; 2012 Sep; 8 Suppl 1():S5-20. PubMed ID: 22846372
[TBL] [Abstract][Full Text] [Related]
14. Internal stimuli-responsive nanocarriers for drug delivery: Design strategies and applications.
Liu M; Du H; Zhang W; Zhai G
Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():1267-1280. PubMed ID: 27987683
[TBL] [Abstract][Full Text] [Related]
15. Hierarchical structured and programmed vehicles deliver drugs locally to inflamed sites of intestine.
Li W; Li Y; Liu Z; Kerdsakundee N; Zhang M; Zhang F; Liu X; Bauleth-Ramos T; Lian W; Mäkilä E; Kemell M; Ding Y; Sarmento B; Wiwattanapatapee R; Salonen J; Zhang H; Hirvonen JT; Liu D; Deng X; Santos HA
Biomaterials; 2018 Dec; 185():322-332. PubMed ID: 30267958
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
Yang C; Merlin D
Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
[TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species-scavenging nanomedicines for the treatment of oxidative stress injuries.
Yoshitomi T; Nagasaki Y
Adv Healthc Mater; 2014 Aug; 3(8):1149-61. PubMed ID: 24482427
[TBL] [Abstract][Full Text] [Related]
18. Stimuli-responsive Carriers for Controlled Intracellular Drug Release.
Sheng Y; Hu J; Shi J; Lee LJ
Curr Med Chem; 2019; 26(13):2377-2388. PubMed ID: 28875840
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease.
Si XY; Merlin D; Xiao B
World J Gastroenterol; 2016 Sep; 22(34):7718-26. PubMed ID: 27678353
[TBL] [Abstract][Full Text] [Related]
20. Bioengineering CXCR4-overexpressing cell membrane functionalized ROS-responsive nanotherapeutics for targeting cerebral ischemia-reperfusion injury.
Luo L; Zang G; Liu B; Qin X; Zhang Y; Chen Y; Zhang H; Wu W; Wang G
Theranostics; 2021; 11(16):8043-8056. PubMed ID: 34335979
[No Abstract] [Full Text] [Related]
[Next] [New Search]
